BioSpace News Archive

Biogen Inc. announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis.

Sanofi Canada is pleased to announce that Health Canada has approved SARCLISA® in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 with the Securities and Exchange Commission on Tuesday, October 12, 2021.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomX’s atopic dermatitis product candidate, BX005, in Japan.

Evelo Biosciences, Inc. today presented preclinical data for EDP1867, a non-live pharmaceutical preparation of a single strain of Veillonella parvula, at ECTRIMS 2021, October 13-15, 2021.

OpSens Inc. is pleased to announce the commencement of the human clinical study utilizing the SavvyWire, and successful treatment of the first patients.

Valeo Pharma Inc. announced today that it has been awarded two multi-year listing agreements by two of Canada’s largest Group Purchasing Organizations (“GPO”) for Redesca as well as three additional hospital specialty products.

Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Axial Therapeutics today announced the completion of a $37.25 million Series C financing.

Taysha Gene Therapies, Inc. today announced sponsored genetic testing for giant axonal neuropathy (GAN) in partnership with GeneDx, Inc.